Telehealth program for weight management and related health issues
OneSTOP (One-Stop Telehealth Obesity Program): the Use of Telecare and Digital Platforms for Multidisciplinary Management of Weight Management and Related Comorbidities
NA · Changi General Hospital · NCT06890169
This study is testing a new telehealth program for weight management to see if it helps obese adults with type 2 diabetes and liver issues lose weight and improve their health better than traditional in-person programs.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 21 Years to 70 Years |
| Sex | All |
| Sponsor | Changi General Hospital (other) |
| Locations | 1 site (Singapore) |
| Trial ID | NCT06890169 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of the OneSTOP Telehealth Obesity Program, which combines teleconsultations and the EMPOWER app, in inducing significant weight loss and metabolic improvements in obese adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD). Participants will be randomly assigned to either the OneSTOP program or a conventional face-to-face weight management program over a 26-week period. The study will compare the outcomes of both approaches in terms of weight loss, patient convenience, and adherence to dietary and exercise recommendations.
Who should consider this trial
Good fit: Ideal candidates are adults aged 21-70 with a BMI greater than 27.5 kg/m2 and suboptimal control of type 2 diabetes or MASLD.
Not a fit: Patients with a life expectancy of less than 6 months or those unable to comply with written instructions in English may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could provide a more accessible and effective method for managing obesity and related metabolic conditions.
How similar studies have performed: Other studies have shown promising results with telehealth approaches for weight management, indicating potential for success in this novel intervention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 21-70 * Body mass index \> 27.5 kg/m2 * Waist circumference \> 90 cm in men or 80 cm in women * Suboptimal control of type 2 diabetes (HbA1c \> 6.5%) AND/OR MASLD (as defined on radiological or histological evidence of hepatic steatosis in the absence of other chronic liver disease) Exclusion Criteria: * Men who drink \> 21 units/week and women who drink \> 14 units/week of alcohol * Participants previously on weight-lowering medications (however if they are keen to participate, there will be a minimum wash-out period of 3 months before participation) * Illness with life expectancy of less than 6 months * Inability to comply with written instructions in English
Where this trial is running
Singapore
- Changi General Hospital — Singapore, Singapore (RECRUITING)
Study contacts
- Principal investigator: Joan Khoo, MBBS, FRCP — Changi General Hospital
- Study coordinator: Joan Khoo, MBBS, FRCP
- Email: joan.khoo.j.c@singhealth.com.sg
- Phone: +65 69365641
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Obesity and Type 2 Diabetes, NAFLD - Non-Alcoholic Fatty Liver Disease, Hypertension, Dyslipidaemia, Telemedicine, obesity, type 2 diabetes, masld